Lenograstim

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Glycosylated granulocyte colony stimulating factor produced by recombinant DNA technology.

IndicationThis section has been translated automatically.

Severe neutropenia in patients with non-myeloidal malignant diseases under cytostatic drugs.

Dosage and method of useThis section has been translated automatically.

150 μg/m2 KO s.c. or i.v. from the day following the chemotherapy until the expected low point is passed and the neutrophil count is normal Application max. 28 days.

Remember! Do not use 1 day before and on the day of chemotherapy because of the increased sensitivity of rapidly dividing myeloid cells!

Undesirable effectsThis section has been translated automatically.

Alopecia, nausea, vomiting, fever, headache, bone pain, leukocytosis, thrombopenia.

Notice! Check your leukocyte and thrombocyte counts regularly!

ContraindicationThis section has been translated automatically.

Pregnancy, lactation, simultaneous cytotoxic chemotherapy.

PreparationsThis section has been translated automatically.

Granocyte

Authors

Last updated on: 29.10.2020